Gum disease and diabetes: new clues from a completed study

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 30 to 70 years on the day of inclusion (30 to 70 years means from the day of the 30th birthday to the day before the 71st birthday) * Body mass index \< 40 kg/m2 * Participants without type 2 diabetes mellitus (T2DM) or pre-diabetes (as confirmed by hemoglobin A1C (HbA1c) \< 5.7%) or Participants diagnosed with T2DM for at least 6 months with HbA1c between 6.5%-7.8% or 8%-10% on the day of screening * Participants without PD (healthy or with gingivitis), or participants diagnosed with stages I/II or stages III/IV PD within 2 weeks of sample collection Exclusion Criteria: * Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating blood sampling * History of human immunodeficiency virus (HIV) infection, or active hepatitis B (HB) or hepatitis C virus infection * Known or recently active (within 12 months) neoplastic disease (including skin cancer) or a current or past diagnosis of any hematologic malignancy (ie, leukemia) * Participants with pre-existing unstable disease, defined as disease requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks prior to enrollment * Active autoimmune disease (eg, rheumatoid arthritis, systemic lupus erythematosus, etc) * Known pregnancy (no pregnancy testing will be performed) * Overt acute illness/infection (according to Investigator's judgment) or febrile illness (temperature ≥ 38.0°C \[100.4°F\]) on the day of inclusion. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided for at least 2 consecutive days prior to enrollment * Receipt of any vaccine within the 4 weeks preceding study enrollment * Receipt of immune globulins, blood, or blood-derived products in the past 3 months * Current or recent (within 3 weeks of enrollment) receipt of systemic antibiotics * Use of chlorhexidine mouthwash for \> 7 days within 3 weeks of enrollment * Receipt of immunomodulators or immunosuppressive therapy, including long-term corticosteroid therapy * Sub-gingival instrumentation/SRP within the 3 months prior to study enrollment Note: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.